How BMS Is Tackling Clinical Trial Diversity
Site Selection Is A Critical Component
Executive Summary
The company’s director of clinical trial diversity strategy, Lorena Kuri, talked to Scrip about how she became interested in trial diversity and what BMS is doing to increase it.
You may also be interested in...
Database In Works To Help Drugmakers Avoid Molecules That Trigger Immune Reactions
Individuals from pharma, biotech, technology and academia create shared database to facilitate development of therapeutic proteins that are unlikely to provoke immune reactions.
Novartis Looks To Take Its Diversity Show On The Road
Head of clinical trial diversity and inclusion Kim Fookes spoke with Scrip about Novartis’s US trial diversity initiatives and early plans to expand them abroad.
BMS Sighs In Relief As Opdivo Returns To Sales Growth
With full-year 2020 and Q1 sales down due to pandemic, the company celebrates the PD-1 therapy’s growth in Q2. CAR-T products Breyanzi, Abecma are off to solid launches but face manufacturing hurdles.